๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University454 Ruijin Hospital276 Shanghai Zhongshan Hospital163 RenJi Hospital135 Children's Hospital of Fudan University84
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shanghai

3827 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety
NCT06531278Pancreatic Cancer Metastatic to Liver
DrugsIrinotecan liposome·Calcium folinate·Adebrelimab·Oxaliplatin
Jiang Long
Phase 2
40
Shanghai
2024-07-16
Recruiting
Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer
NCT06496373Pancreatic Cancer Resectable, Chemotherapy-intolerant
DrugPersonalized neoantigen tumor vaccine
Ruijin Hospital
Phase EARLY_PHASE1
20
Shanghai
2024-07-16
Recruiting
Safety and Efficacy Study of NGGT002 in Adult Patients With Phenylketonuria
NCT06687733Phenylketonurias
NGGT (Suzhou) Biotechnology Co., Ltd.
Phase 1/2
18
Bengbu, Shanghai
2024-07-16
Not yet open
Remimazolam Besylate and Propofol Sedation on Hemodynamic for Coronary Artery Bypass Graft Patients
NCT06496165Coronary Artery Disease
Shanghai Zhongshan Hospital
Not applicable
338
Shanghai
2024-07-15
Recruiting
Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)
NCT06511349Type 1 Primary Hyperoxaluria
DrugYOLT-203
RenJi Hospital
Phase EARLY_PHASE1
21
Shanghai
2024-07-15
Recruiting
Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer
NCT06503380Hematological Toxicity, Targeted Therapy, Breast Cancer
Fudan University
Observational
1,000
Shanghai
2024-07-15
Recruiting
Effects of Intermittent Dietary Restriction on Cardiometabolic Risk in School-aged Children
NCT06500078Cardiovascular Syndrome, Metabolic
Children's Hospital of Fudan University
Not applicable
324
Shanghai
2024-07-13
Recruiting
High-Intensity Interval Training(HIIT) on Cardio-metabolic Risk in School-age Children
NCT06416488Cardiovascular Syndrome, Metabolic
Children's Hospital of Fudan University
Not applicable
336
Shanghai
2024-07-13
Recruiting
A Clinical Study of B007 in the Treatment of Pemphigus.
NCT06454357Pemphigus
DrugB007
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
132
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Jinan, Shanghai
2024-07-12
Recruiting
Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients
NCT06212076Solid Tumor
DrugIPG1094
Nanjing Immunophage Biotech Co., Ltd
Phase 1/2
60
Shanghai
2024-07-11
Recruiting
Adjuvant Radiotherapy in High Risk Locally Advanced DTC
NCT06558981Thyroid Cancer
Fudan University
Phase 3
124
Shanghai
2024-07-11
Recruiting
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
NCT06496308Mantle Cell Lymphoma (MCL)
DrugsBendamustine·Orelabrutinib·Rituximab·Venetoclax
Ruijin Hospital
Phase 3
78
Shanghai
2024-07-10
Recruiting
LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
NCT06387628TNBC - Triple-Negative Breast Cancer
Fudan University
Phase 2
74
Shanghai
2024-07-10
Recruiting
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
NCT06024746Heart Failure
DrugsEmpagliflozin·Finerenone
Colorado Prevention Center
Phase 3
1,500
Guangzhou, Changsha, Jinan, Shanghai, Taiyuan, Xian City, Chengdu, Tianjin
2024-07-09
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
DrugIvosidenib
Servier Bio-Innovation LLC
Phase 3
136
Guangzhou, Wuhan, Shang'ai, Shanghai, Chengdu, Hangzhou, Beijing
2024-07-09
Recruiting
Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
NCT06235203Recurrent Nasopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
Phase 3
154
Shanghai, Fuzhou, Nanning, Shenzhen
2024-07-09
Active, closed
A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
NCT06385678Advanced KRAS G12D Mutant Solid Tumors
DrugsSHR-9839·HRS-4642·Adebrelimab·Pemetrexed
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
47
Shanghai
2024-07-05
Recruiting
Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours
NCT06453057Adult
DrugGT307
Grit Biotechnology
Not applicable
18
Shanghai
2024-07-04
Recruiting
A Study of SKB518 in Patients With Advanced Solid Tumors
NCT06428331Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
150
Shanghai
2024-07-04
Recruiting
ARTEMIS-008๏ผšHS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
NCT06498479Small Cell Lung Cancer
DrugsHS-20093·Topotecan
Hansoh BioMedical R&D Company
Phase 3
460
Beijing, Harbin, Zhengzhou, Changchun, Shenyang, Jinan, Shanghai, Guangzhou
2024-07-04
Recruiting
A Study of FZ-AD005 in Patients With Advanced Solid Tumors
NCT06424665Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 1
162
Changsha, Shanghai, Hangzhou
2024-07-03
Recruiting
AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy
NCT06494995Head and Neck Squamous Cell Carcinoma
DrugsCadonilimab·Capecitabine
Fudan University
Phase 2
52
Shanghai
2024-07-03
By invitation
Real-world Study of Acalabrutinib
NCT06767891Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Ruijin Hospital
Observational
160
Shanghai
2024-07-02
Recruiting
Transcranial Magnetic Stimulation Synchronized with Motor Task Training for Post-Stroke Rehabilitation
NCT06849505Stroke, Upper Extremity Parasis
First Affiliated Hospital of the Chinese People's Liberation Army Naval Medical University
Not applicable
15
Shanghai
2024-07-02
Active, closed
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Severe AADC Deficiency
NCT06432140Aromatic L-amino Acid Decarboxylase Deficiency
Shanghai Vitalgen BioPharma Co., Ltd.
Phase 2/3
13
Shanghai
2024-07-02
Recruiting
RW Study of Adjuvant Radiotherapy in Locally Advanced Thyroid Cancer
NCT06524167Thyroid Cancer
Fudan University
Observational
80
Shanghai
2024-07-02
Recruiting
Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.
NCT06483906Acute Myeloid Leukemia
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2
56
Shanghai
2024-07-02
Recruiting
FeNO Observation Study in ICU Patients With ARS
NCT06680895Compare the Concentration of Exhaled Nitric Oxide in Patients With Different Severity of RF
Shanghai Zhongshan Hospital
Observational
1,000
Shanghai
2024-07-01
Recruiting
Risk Evaluation by COronary Imaging and Artificial intelliGence Based fuNctIonal analyZing tEchniques - IV
NCT06793787Coronary Artery Disease, Coronary Atheroscleroses, Acute Coronary Syndromes (ACS), Chronic Coronary Syndrome
Ruijin Hospital
Observational
200
Shanghai
2024-07-01
Not yet open
Predicting Adverse Kidney Events of Cardiac Surgery-Associated Acute Kidney Injury Using Novel Biomarkers
NCT06351813Acute Kidney Injury, Critical Illness, Kidney Failure
Shanghai Zhongshan Hospital
Observational
358
Shanghai
2024-07-01
Active, closed
CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT
NCT06449586Hematologic Malignancy
DrugLetermovir
Ruijin Hospital
Phase 3
250
Wuhan, Shanghai, Hangzhou
2024-07-01
Recruiting
Evaluation of Vulnerability of Carotid Plaques and Prediction of Cardio-Cerebrovascular Event Using Ultrasonic Imaging
NCT06473272Carotid Plaque, Ischemic Stroke, Cardiovascular Events
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Observational
600
Shanghai
2024-07-01
Not yet open
Combining Chemoradiotherapy With Sintilimab in First-Line ICC
NCT06447454ICC
Shanghai Zhongshan Hospital
Observational
19
Shanghai
2024-07-01
Active, closed
Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC
NCT06448910NSCLC, Locally Advanced Lung Carcinoma
DrugCadonilimab
Fudan University
Phase 2
41
Shanghai
2024-07-01
Recruiting
Risk Evaluation by COronary Imaging and Artificial intelliGence Based fuNctIonal analyZing tEchniques - III
NCT06793774Coronary Artery Disease, Coronary Atheroscleroses, Acute Coronary Syndromes (ACS)
Ruijin Hospital
Observational
300
Shanghai
2024-07-01
Recruiting
Segmentectomy for Solid-dominant Lung Cancer
NCT06634966Segmentectomy, Lung Adenocarcinoma
Fudan University
Phase 3
277
Shanghai
2024-07-01
Not yet open
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
NCT06456138KRAS Mutation-Related Tumors, Advanced Lung Cancer, Refractory Tumor
DrugsTrametinib·Dexamethasone·Tislelizumab
Shanghai Chest Hospital
Phase 1/2
60
Shanghai
2024-07-01
Not yet open
Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria
NCT06469229Hematuria, Urothelial Carcinoma, Bladder Cancer, Ureter Cancer
Changhai Hospital
Observational
1,200
Shanghai
2024-07-01
Recruiting
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
NCT06501391NSCLC Stage IV, Brain Metastases
Fudan University
Phase 2
54
Shanghai
2024-07-01
Recruiting
DRug-coAted Balloon Compared With cuttinG balloON in Treatment of Arteriovenous Fistula Stenosis
NCT06527963Arteriovenous Fistula, Angioplasty, Balloon, Hemodialysis Access Failure
RenJi Hospital
Observational
180
Zhengzhou, Nanjing, Shanghai
2024-07-01
Recruiting
Calcium Folinate Treatment of Spastic Paraplegia 56
NCT06478238Hereditary Spastic Paraplegia
DrugCalcium folinate
Shanghai 6th People's Hospital
Phase EARLY_PHASE1
10
Shanghai
2024-07-01
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
420
Beijing, Guangzhou, Shanghai
2024-07-01
Active, closed
CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer
NCT07801352Locally Advanced Colorectal Cancer, Metastatic Colorectal Cancer
DrugsDihydroartemisinin·Oxaliplatin·Capecitabine·Tislelizumab
Shanghai Changzheng Hospital
Phase 2
15
Shanghai
2024-07-01
Not yet open
Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)
NCT06502080Biliary Tract Cancer
Shanghai Zhongshan Hospital
Phase 2
128
Shanghai
2024-07
Recruiting
The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP
NCT06479291Immune Thrombocytopenia With Positive ANA Antibodies
Yunfeng Cheng
Not applicable
126
Shanghai
2024-07
Not yet open
TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors
NCT06500091Soft Tissue Sarcoma, Melanoma
DrugsTQB2916·Doxorubicin Hydrochloride·Penpulimab
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
54
Beijing, Zhengzhou, Changsha, Changchun, Jinan, Shanghai, Taiyuan, Tianjin
2024-07
Recruiting
A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma
NCT06494371Hodgkin's Lymphoma, Anaplastic Large Cell Lymphoma
Ruijin Hospital
Phase 1
32
Shanghai
2024-07
Recruiting
Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma
NCT06596954Esophageal Squamous Cell Cancer
Ruijin Hospital
Not applicable
212
Shanghai
2024-06-30
Recruiting
Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
NCT06518655Pulmonary Nodules, Multiple, Pulmonary Nodules, Solitary, Lung Cancer
ChromX Health
Observational
3,000
Beijing, Foshan, Guangzhou, Wuhan, Shanghai, Chengdu
2024-06-30
Active, closed
Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors
NCT06462222Leptomeningeal Metastasis
Guangzhou Medical University
Phase 1/2
45
Huizhou, Beijing, Shanghai
2024-06-30
Recruiting
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
DrugsZongertinib·Zanidatamab·MFOLFOX6·Trastuzumab emtansine
Boehringer Ingelheim
Phase 1/2
768
Changchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou
2024-06-28
Recruiting
A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis
NCT06498089Takayasu Arteritis
DrugsAdalimumab·Tofacitinib·Methotrexate·Tocilizumab
Shanghai Zhongshan Hospital
Phase 4
124
Shanghai
2024-06-28
Recruiting
Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Advanced Colorectal Cancer
NCT06819280Adult
DrugGT307
Grit Biotechnology
Not applicable
18
Shanghai
2024-06-28
Recruiting
Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients
NCT06394063Systemic Lupus Erythematosus
DrugTelitacicept
RenJi Hospital
Not applicable
176
Shanghai
2024-06-28
Recruiting
A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT06469008Head and Neck Squamous Cell Carcinomas, Solid Tumor
DrugBL-B16D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
21
Shanghai
2024-06-27
Recruiting
A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors
NCT06413953Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
140
Guangzhou, Zhuhai, Chengde, Harbin, Changsha, Changzhou, Binzhou, Shanghai
2024-06-27
Recruiting
An Exploratory Clinical Study of CD19 CAR NK Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
NCT06464679Autoimmune Diseases
Changhai Hospital
Phase 1
72
Shanghai
2024-06-27
Recruiting
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2)
NCT05224960Decompensated Cirrhosis
DrugUC-MSCs
Beijing 302 Hospital
Phase 2
140
Lanzhou, Guangzhou, Sanya, Wuhan, Shanghai, Kashgar, Beijing
2024-06-27
Recruiting
Efficacy of Hi-tACS for Schizophrenia Negative Symptoms
NCT06888726Schizophrenia; Negative Type, Transcranial Alternating Current Stimulation
Shanghai Mental Health Center
Not applicable
60
Shanghai
2024-06-27
Recruiting
Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC
NCT06494943Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
DrugsCis-platinum·Paclitaxel·Tislelizumab
Fudan University
Phase 1/2
27
Shanghai
2024-06-26
Recruiting
Evaluate LAE102 in Healthy and Overweight/Obese Subjects
NCT06493084Overweight and Obese Volunteers
Laekna Limited
Phase 1
160
Shanghai
2024-06-25
Recruiting
Adjuvant vs Surgery Only in Early-stage Recurrent NPC
NCT06228079Recurrent Nasopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
Phase 3
176
Shanghai, Fuzhou, Nanning, Shenzhen
2024-06-25
Recruiting
A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in mPCa Patients
NCT06469710Prostate Cancer, Circulating Tumor Cell, Leukapheresis
RenJi Hospital
Observational
50
Shanghai
2024-06-25
Recruiting
Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation
NCT06536400Solid Tumors
DrugHSK42360
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
316
Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Changsha, Nanjing, Shanghai
2024-06-25
Recruiting
Efficacy and Safety Study of 610 in Patients With Severe Asthma
NCT06323213Asthma
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 3
480
Shanghai
2024-06-24
Active, closed
LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.
NCT06351020Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
DrugsLM-302·Apatinib·Irinotecan
LaNova Medicines Zhejiang Co., Ltd.
Phase 3
387
Beijing, Shanghai
2024-06-24
Recruiting
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06307795Locally Advanced or Metastatic Solid Tumors
DrugANS014004
Avistone Biotechnology Co., Ltd.
Phase 1
63
Beijing, Harbin, Zhengzhou, Jinan, Shanghai
2024-06-24
Active, closed
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)
NCT06382142Triple-Negative Breast Cancer
DrugsVinorelbine·Eribulin·Iza-bren·Capecitabine
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
418
Shanghai
2024-06-21
Recruiting
An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy
NCT06469190Nephropathy
Changhai Hospital
Phase EARLY_PHASE1
36
Shanghai
2024-06-21
Recruiting
68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer.
NCT06608160PET / CT, Lung Carcinoma, Immunotherapy
Ruijin Hospital
Observational
30
Shanghai
2024-06-20
Active, closed
First-line Regimen With QL1706 Plus Chemo ยฑ Bev in PDAC Patients
NCT06313970Pancreatic Cancer
DrugsIparomlimab and Tuvonralimab·Nab-paclitaxel·Gemcitabine·Bevacizumab
Fudan University
Phase 2
58
Shanghai
2024-06-20
Recruiting
A Trial on the Recurrence Free Survival Rate of Type I AIP With High-risk of Recurrence
NCT06468709Type 1 AIP
Ruijin Hospital
Phase 4
86
Shanghai
2024-06-20
Recruiting
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
NCT06428409Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
DrugsLevoleucovorin·Leucovorin·Sacituzumab tirumotecan·Cisplatin
Merck Sharp & Dohme LLC
Phase 1/2
220
Beijing, Fuzhou, Wuhan, Changsha, Shanghai, Chengdu
2024-06-20
Recruiting
Tirilizumab with Albumin-bound Paclitaxel and Cisplatin for Locally Advanced Resectable Oral Squamous Cell Carcinoma
NCT06470217Locally Advanced Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2
116
Shanghai
2024-06-19
Not yet open
Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction
NCT06469060Esophageal Cancer
Shanghai Chest Hospital
Phase 2
34
Shanghai
2024-06-19
Recruiting
A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors
NCT06468358Solid Tumor
DrugsLB4330·LB1410
L & L Bio Co., Ltd., Ningbo, China
Phase 1/2
194
Shanghai
2024-06-19
Recruiting
AMT-676 in Patients With Advanced Solid Tumors
NCT06400485Advanced Solid Tumors
DrugAMT-676
Multitude Therapeutics Inc.
Phase EARLY_PHASE1
24
Fuzhou, Guangzhou, Shanghai, Chengdu, Hangzhou
2024-06-18
Active, closed
To Compare Efficacy and Safety of CMAB007 and Xolairยฎ in Patients With Chronic Spontaneous Urticaria
NCT06365879Chronic Spontaneous Urticaria
DrugOmalizumab
Taizhou Mabtech Pharmaceutical Co.,Ltd
Phase 3
392
Shanghai
2024-06-18
Recruiting
Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors
NCT07584954Solid Tumor Cancer, Solid Tumor Cancer Treatment With Immunotherapy
Jun Zhou
Phase 1
90
Fuzhou, Anyang, Jinan, Shanghai
2024-06-18
Recruiting
A Long-term Follow-up Study in Participants Who Received CS-101
NCT06479616Beta-Thalassemia
Children's Hospital of Fudan University
Not applicable
5
Shanghai
2024-06-18
Recruiting
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
NCT06316856T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia, T-cell Malignancies
Beijing GoBroad Hospital
Phase 1/2
54
Beijing, Shanghai, Chengdu
2024-06-18
Recruiting
Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
NCT06427239Pancreatic Cancer
DrugsHRS-4642·SHR-8068·Adebrelimab·Bevacizumab
Fudan University
Phase 1/2
130
Shanghai
2024-06-17
Recruiting
Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)
NCT06385730Esophageal Cancer
DrugNeoadjuvant anti-PD-1
Shanghai Chest Hospital
Phase 2
60
Shanghai
2024-06-17
Recruiting
A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
NCT06378593Solid Tumors With FGFR2 Alterations, Adult
Drug3HP-2827
3H (Suzhou) Pharmaceuticals Co., Ltd.
Phase 1/2
130
Beijing, Shanghai
2024-06-17
Active, closed
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
NCT05562947Neovascular Age-related Macular Degeneration, nAMD
DrugRanibizumab
Hoffmann-La Roche
Phase 3
68
Beijing, Chengdu, Guangzhou, Harbin, Qingdao, Shanghai, Shenyang, Taiyuan
2024-06-17
Not yet open
F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus Erythematosus
NCT06468683Lupus Erythematosis
Shanghai Simnova Biotechnology Co.,Ltd.
Phase 1
50
Shanghai
2024-06-15
Recruiting
The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.
NCT06597526Peritoneal Metastasis, Gastric Cancer
Ruijin Hospital
Observational
30
Shanghai
2024-06-15
Recruiting
A Study of IBI363 in Subjects With Advanced Malignancies
NCT06468098Advanced Malignancies
DrugIBI363
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
556
Shanghai
2024-06-15
Recruiting
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
NCT06437509Extensive-stage Small-cell Lung Cancer
DrugIza-bren
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
66
Shanghai
2024-06-13
Recruiting
Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis
NCT06414135Systemic Sclerosis
Liangjing Lu
Phase 1
6
Shanghai
2024-06-12
Recruiting
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)
NCT06611813HR+/HER2- Breast Cancer
First Affiliated Hospital of Zhejiang University
Phase 2
30
Hangzhou, Harbin, Hefei, Jinhua, Nanchang, Shanghai, รœrรผmqi, Xi'an
2024-06-11
Recruiting
A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms
NCT06398444Advanced Neuroendocrine Neoplasm
DrugLutetium[177Lu] Oxodotreotide
Sinotau Pharmaceutical Group
Phase 2/3
85
Shanghai
2024-06-11
Recruiting
Study on the Safety and Efficacy of Sodium Phosphate Powder for Intestinal Preparation in People Aged 50 to 70 Years Old
NCT06652906Physical Examination
RenJi Hospital
Phase 2
8
Shanghai
2024-06-11
Active, closed
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
NCT06472076Lung Cancer, Non-Small Cell
DrugsBelrestotug·Dostarlimab·Pembrolizumab
GlaxoSmithKline
Phase 3
88
Chengdu, Hangzhou, Hefei, Nanjing, Shanghai
2024-06-10
Recruiting
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT06437522Head and Neck Squamous Cell Carcinoma
DrugIza-bren
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
46
Shanghai
2024-06-07
Recruiting
Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
NCT06407947Multiple Myeloma
Shanghai Changzheng Hospital
Phase EARLY_PHASE1
10
Shanghai
2024-06-06
Recruiting
Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children
NCT06440915Aspergillosis Invasive, Mucormycosis
DrugIsavuconazole
Shanghai Children's Medical Center
Not applicable
200
Shanghai
2024-06-06
Recruiting
Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma
NCT06528847Non-Small Cell Lung Cancer
DrugEtoposide
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
62
Shanghai
2024-06-05
Recruiting
A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Pre-COPD Outcomes in Chinese Population
NCT06724848COPD
AstraZeneca
Observational
850
Beijing, Changsha, Chengdu, Guangzhou, Hefei, Nanjing, Nanning, Shanghai
2024-06-05
Not yet open
Efficacy and Safety of Multimode Thermal Therapy in the Treatment of Early Peripheral Lung Cancer
NCT06453889Lung Cancer
Shanghai Chest Hospital
Not applicable
10
Shanghai
2024-06-05
Rows per page Showing 2401–2500 of 3827
Previous 23 24 25 26 27 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai?page=25

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,827 of those studies with a site in Shanghai.

How many clinical trials are recruiting in Shanghai?

2,393 of the 3,827 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 737 have not yet opened recruitment, 588 are active but closed to new participants, and 109 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.